Anna M. Varghese

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

  Clinical Cancer Research · 2026-06-26

• Organotropic and genomic characterization of pancreatic neuroendocrine carcinoma.

  Journal of Clinical Oncology · 2026-05-27

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-04-18

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-03-26 · 2 citations

• Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

  Nature Medicine · 2026-03-25 · 3 citations

• POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-03-17

• Data from A Phase II Trial of an Extended-Release siRNA Implant Targeting <i>KRAS</i><sup>G12D/V</sup> in Locally Advanced Pancreatic Cancer

  2026-03-16

• Supplementary Table S1 from A Phase II Trial of an Extended-Release siRNA Implant Targeting <i>KRAS</i><sup>G12D/V</sup> in Locally Advanced Pancreatic Cancer

  2026-03-16

• Supplementary Figure S1 from A Phase II Trial of an Extended-Release siRNA Implant Targeting <i>KRAS</i><sup>G12D/V</sup> in Locally Advanced Pancreatic Cancer

  2026-03-16

• Dual pancreatic carcinomas: clonally related or independent primaries?

  npj Precision Oncology · 2026-02-07

• A Phase II Trial of an Extended-Release siRNA Implant Targeting <i>KRAS</i> G12D/V in Locally Advanced Pancreatic Cancer

  Clinical Cancer Research · 2026-01-13 · 4 citations

• Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

  Journal for ImmunoTherapy of Cancer · 2026-01-01 · 4 citations

• Abstract B047: DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance

  Cancer Research · 2025-09-28

• Abstract B044: Black and Hispanic patients with pancreatic ductal adenocarcinoma (PDAC) have worse overall survival than Asian and White patients with PDAC, despite having more favorable genetic profiles

  Cancer Research · 2025-09-28

• Clinico-genomic Characterization of PALB2-Mutated Pancreatic Adenocarcinoma

  International Journal of Cancer Care and Delivery · 2025-09-26

• Abstract A097: Impact of socioeconomic status on survival outcomes in patients with stage IV pancreatic adenocarcinoma: A race/ethnicity controlled analysis

  Cancer Epidemiology Biomarkers & Prevention · 2025-09-18

• Maximal Ablative Irradiation Because of Encasement for Patients with Potentially Resectable Locally Advanced Pancreatic Cancer: Final Results of Phase II MAIBE Trial

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

• Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialPreprint

  Research Square · 2025-09-01 · 3 citations

• Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

  JNCI Journal of the National Cancer Institute · 2025-06-13 · 4 citations

• Clinico-genomic characterization of <i>PALB2</i> -mutated pancreatic adenocarcinoma.

  Journal of Clinical Oncology · 2025-05-28